UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Get Our Latest Analysis on United Therapeutics United Therapeutics Price Performance NASDAQ UTHR opened at $351.17 on Friday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month ...

Silver Spring, MD-based United Therapeutics Corporation markets four ... and intravenous (IV) use. UTHR is a #2 (Buy) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

UTHR boasts an average earnings surprise of 4.2%. On a historic basis, United Therapeutics has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% this year.